{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:53:33Z","timestamp":1759366413338,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.revmed.2006.10.326","type":"journal-article","created":{"date-parts":[[2006,11,4]],"date-time":"2006-11-04T07:14:12Z","timestamp":1162624452000},"page":"232-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Traitement des\u00a0uv\u00e9ites chroniques non infectieuses"],"prefix":"10.1016","volume":"28","author":[{"given":"D.","family":"Le Thi Huong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lehoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Piette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2006.10.326_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00005792-200107000-00005","article-title":"Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center","volume":"80","author":"Bodaghi","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2006.10.326_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"The SUN working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international worshop","volume":"140","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib3","first-page":"492","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2006.10.326_bib4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/archopht.123.5.682","article-title":"Non infectious uveitis. A scarcity of randomized clinical trials","volume":"123","author":"Okada","year":"2005","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/jnci\/86.19.1450","article-title":"Risk of leukemia following treatment for non-Hodgkin's lymphoma","volume":"86","author":"Travis","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.revmed.2006.10.326_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-132-8-200004180-00005","article-title":"Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone","volume":"132","author":"Costedoat-Chalumeau","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.revmed.2006.10.326_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/ar1957","article-title":"Anti-inflammatory and immunosuppressive drugs and reproduction","volume":"8","author":"Ostensen","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.revmed.2006.10.326_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin versus pulsed cyclophosphamide in Beh\u00e7et\u2019s syndrome: a single masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/0-306-48382-3_116","article-title":"Azathioprine and low dose pulse cyclophosphamide in severe ocular lesions of Behcet's disease. A preliminary report","volume":"528","author":"Shahram","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.revmed.2006.10.326_bib10","first-page":"123","article-title":"Treatment of severe refractory uveitis with intravenous cyclophosphamide","volume":"21","author":"Rosenbaum","year":"1994","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.revmed.2006.10.326_bib11","first-page":"438","article-title":"Bolus de cyclophosphamide et de m\u00e9thylprednisolone dans l\u2019uv\u00e9ite de la maladie de Beh\u00e7et. R\u00e9sultats pr\u00e9liminaires avec utilisation de nouveaux crit\u00e8res d\u2019\u00e9valuation","volume":"143","author":"Hamza","year":"1992","journal-title":"Ann. Med. Interne (Paris)"},{"key":"10.1016\/j.revmed.2006.10.326_bib12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ophtha.2003.08.034","article-title":"Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety","volume":"111","author":"Durrani","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2006.10.326_bib13","first-page":"2571","article-title":"Risk of ovarian failure and fertility after intravenous cyclophosphamide therapy. A study in 84 patients","volume":"29","author":"Le Thi Huong","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.revmed.2006.10.326_bib14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-126-4-199702150-00005","article-title":"Use of testosterone to prevent cyclophosphamide-induced azoospermia","volume":"126","author":"Masala","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.revmed.2006.10.326_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Behcet's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2006.10.326_bib16","first-page":"499","article-title":"Treatment of uveitis with azathioprine","volume":"87","author":"Newell","year":"1967","journal-title":"Trans. Ophthalmol. Soc. U. K."},{"key":"10.1016\/j.revmed.2006.10.326_bib17","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0161-6420(02)01097-7","article-title":"Successful treatment of serpiginous choroiditis with alkylating agents","volume":"109","author":"Akpek","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2006.10.326_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/09273940490912407","article-title":"Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression","volume":"13","author":"Becker","year":"2005","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.revmed.2006.10.326_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ophtha.2004.12.036","article-title":"Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy","volume":"112","author":"Kiss","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2006.10.326_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0181-5512(05)81020-4","article-title":"Diagnostic et traitement du syndrome de Voght-Koyanagi-Harada","volume":"28","author":"Touitou","year":"2005","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib21","first-page":"362","article-title":"Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis","volume":"32","author":"Foeldvari","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.revmed.2006.10.326_bib22","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bjo.2004.054239","article-title":"The use of low dose methotrexate in children with chronic anterior and intermediate uveitis","volume":"89","author":"Malik","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1076\/ocii.9.1.35.3983","article-title":"Use of methotrexate in the management of sight-threatening uveitis","volume":"9","author":"Bom","year":"2001","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.revmed.2006.10.326_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1076\/ocii.11.2.131.15919","article-title":"Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis","volume":"11","author":"Kaplan-Messas","year":"2003","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.revmed.2006.10.326_bib25","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0161-6420(01)00576-0","article-title":"Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients","volume":"108","author":"Samson","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2006.10.326_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/0-306-48382-3_118","article-title":"High dose methotrexate for ocular lesions of Behcet's disease. Preliminary short-term results","volume":"528","author":"Davatchi","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.revmed.2006.10.326_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0161-6420(99)90011-8","article-title":"Methotrexate treatment for sarcoid-associated panuveitis","volume":"106","author":"Dev","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2006.10.326_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1076\/ocii.11.2.79.15918","article-title":"Methotrexate in inflammatory eye disease","volume":"11","author":"Stawell","year":"2003","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.revmed.2006.10.326_bib29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1076\/ocii.11.2.131.15919","article-title":"Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis","volume":"11","author":"Barkana","year":"2003","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.revmed.2006.10.326_bib30","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0161-6420(92)31790-7","article-title":"Low-dose methotrexate therapy for ocular inflammatory disease","volume":"99","author":"Shah","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2006.10.326_bib31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0002-9394(14)76692-9","article-title":"Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis","volume":"112","author":"Nussenblatt","year":"1991","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Beh\u00e7et\u2019s disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2006.10.326_bib33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1021227019915","article-title":"Long-term therapy with low dose cyclosporin A in ocular Behcet's disease","volume":"105","author":"Ozdal","year":"2002","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1034\/j.1600-0420.1998.760118.x","article-title":"Cyclosporin-A therapy in severe uveitis of Behcet's disease","volume":"76","author":"Sullu","year":"1998","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.revmed.2006.10.326_bib35","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1097\/01.ASN.0000034945.61533.26","article-title":"Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study","volume":"13","author":"Isnard-Bagnis","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.revmed.2006.10.326_bib36","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0161-6420(99)90156-2","article-title":"Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine","volume":"106","author":"Sloper","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2006.10.326_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1076\/ocii.6.2.101.4051","article-title":"Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis","volume":"6","author":"Kilmartin","year":"1998","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.revmed.2006.10.326_bib38","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0002-9394(14)72551-6","article-title":"FK506 treatment of noninfectious uveitis","volume":"118","author":"Ishioka","year":"1994","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0002-9394(14)73645-1","article-title":"A clinical trial of FK506 in refractory uveitis","volume":"115","author":"Mochizuki","year":"1993","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib40","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib41","first-page":"1","article-title":"Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis. A retrospective analysis of 106 patients","volume":"15","author":"Siepmann","year":"2005","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1046\/j.1442-9071.2003.00704.x","article-title":"Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation","volume":"31","author":"Lau","year":"2003","journal-title":"Clin. Experiment. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib43","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0161-6420(03)00570-0","article-title":"Mycophenolate mofetil for the treatment of scleritis","volume":"110","author":"Sen","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2006.10.326_bib44","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0161-6420(03)00092-7","volume":"110","author":"Thorne","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2006.10.326_bib45","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0161-6420(03)00092-7","article-title":"Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders","volume":"110","author":"Baltatzis","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2006.10.326_bib46","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.revmed.2006.10.326_bib47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/ard.62.5.492","article-title":"Effects of interferon alpha treatment on the clinical course of refractory Behcet\u2019s disease: an open study","volume":"62","author":"Calguneri","year":"1993","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2006.10.326_bib48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","article-title":"Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease","volume":"8","author":"Wechsler","year":"2000","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.revmed.2006.10.326_bib49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","article-title":"Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.revmed.2006.10.326_bib50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/09273940490518865","article-title":"Interferon alpha-2a treatment for serpiginous choroiditis","volume":"13","author":"Sobaci","year":"2005","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.revmed.2006.10.326_bib51","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","article-title":"Interferon as a treatment for uveitis associated with multiple sclerosis","volume":"89","author":"Becker","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib52","article-title":"Efficacy and tolerance of interferon alpha in the treatment of refractory and sight-threatening uveitis: a monocentric study of 45 patients","author":"Bodaghi","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2006.10.326_bib53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Behcet disease: review of the literature","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.revmed.2006.10.326_bib54","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-\u03b1 therapy for sight threatening uveitis","volume":"89","author":"Linstedt","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.revmed.2006.10.326_bib55","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/ard.2004.025882","article-title":"Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors","volume":"64","author":"Bodaghi","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2006.10.326_bib56","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Beh\u00e7et\u2019s disease. An open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum."}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866306007442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866306007442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:20:38Z","timestamp":1759335638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866306007442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0248866306007442"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2006.10.326","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement des\u00a0uv\u00e9ites chroniques non infectieuses","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2006.10.326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}